ConductScience.org, home

Paper19082467

The expression of CRM1 is associated with prognosis in human osteosarcoma.

Yao Y and 8 others. Oncol Rep, 2009. Cited by 138 papers, by iCite.

Cite this record

ConductScience Library. The expression of CRM1 is associated with prognosis in human osteosarcoma. Papers, record 19082467. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19082467

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The expression of CRM1 is associated with prognosis in human osteosarcoma.
PubMed
Journal
Oncol Rep
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
138
iCite
Relative citation ratio, by iCite
2.65
iCite
Revised in PubMed
2026-01-28
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yao YYang
2Dong YYang
3Lin FFeng
4Zhao HHui
5Shen ZZan
6Chen PPing
7Sun YJYuan-Jue
8Tang LNLi-Na
9Zheng SEShui-Er

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone NeoplasmsMajor topic
KaryopherinsMajor topic
OsteosarcomaMajor topic
Receptors, Cytoplasmic and NuclearMajor topic
Adolescent
Adult
Alkaline Phosphatase
Blotting, Western
Child
Child, Preschool
Female
Humans
Kaplan-Meier Estimate
L-Lactate Dehydrogenase
Male
Middle Aged
Prognosis
Exportin 1 Protein

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06114004Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)Background

Source ClinicalTrials.gov

Download CSV of trials

Cited by98

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 138 citations.

PMIDTitleJournalYearIn PapersSource
39165691Cancer-specific alterations in nuclear matrix proteins determined by multi-omics analyses of ductal carcinoma in situ.Front Oncol2024https://conductscience.org/library/papers/39165691PubMed
39161560Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.Oncol Rev2024https://conductscience.org/library/papers/39161560PubMed
38892287Michael Acceptors as Anti-Cancer Compounds: Coincidence or Causality?Int J Mol Sci2024https://conductscience.org/library/papers/38892287PubMed
38783482The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.Clin Transl Med2024https://conductscience.org/library/papers/38783482PubMed
38302473Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma.Nat Commun2024https://conductscience.org/library/papers/38302473PubMed
38186637Treatment of multiple myeloma with selinexor: a review.Ther Adv Hematol2024https://conductscience.org/library/papers/38186637PubMed
38031942CRM1 expression: association with high prognostic value in laryngeal cancer.Turk J Med Sci2023https://conductscience.org/library/papers/38031942PubMed
36920247A general method for quantitative fractionation of mammalian cells.J Cell Biol2023https://conductscience.org/library/papers/36920247PubMed
36827679Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects.Blood Adv2023https://conductscience.org/library/papers/36827679PubMed
35116322Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis.Transl Cancer Res2021https://conductscience.org/library/papers/35116322PubMed
34975332Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis.Int J Biol Sci2022https://conductscience.org/library/papers/34975332PubMed
34944778Therapeutic Targeting of Exportin-1 in Childhood Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34944778PubMed
34583979Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.Mol Cancer Ther2021https://conductscience.org/library/papers/34583979PubMed
34575598Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors.Pharmaceutics2021https://conductscience.org/library/papers/34575598PubMed
34562230Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.Invest New Drugs2022https://conductscience.org/library/papers/34562230PubMed
34502125Measuring and Interpreting Nuclear Transport in Neurodegenerative Disease-The Example of C9orf72 ALS.Int J Mol Sci2021https://conductscience.org/library/papers/34502125PubMed
34188179Disruption of nucleocytoplasmic trafficking as a cellular senescence driver.Exp Mol Med2021https://conductscience.org/library/papers/34188179PubMed
34165175Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.Oncol Rep2021https://conductscience.org/library/papers/34165175PubMed
33909232Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.Invest New Drugs2021https://conductscience.org/library/papers/33909232PubMed
33856525Selinexor decreases HIF-1α via inhibition of CRM1 in human osteosarcoma and hepatoma cells associated with an increased radiosensitivity.J Cancer Res Clin Oncol2021https://conductscience.org/library/papers/33856525PubMed

See all 98 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALPP250PubTator's text mininghttps://conductscience.org/library/genes/250NCBI Gene
XPO17514PubTator's text mininghttps://conductscience.org/library/genes/7514NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19082467

GET https://conductscience.org/api/papers/v1/19082467/cited_by?page=2